Craig Hallum Boosts CareDx (NASDAQ:CDNA) Price Target to $22.00

CareDx (NASDAQ:CDNAFree Report) had its price objective raised by Craig Hallum from $15.00 to $22.00 in a report issued on Friday morning, Benzinga reports. They currently have a buy rating on the stock.

Several other research analysts have also recently weighed in on CDNA. The Goldman Sachs Group raised their target price on CareDx from $10.00 to $14.00 and gave the company a buy rating in a research note on Monday, May 13th. HC Wainwright reissued a neutral rating on shares of CareDx in a research report on Wednesday, May 15th. Raymond James downgraded CareDx from an outperform rating to a market perform rating in a research note on Monday, May 13th. Stephens lifted their price objective on shares of CareDx from $15.00 to $18.00 and gave the company an overweight rating in a research note on Monday, May 13th. Finally, StockNews.com upgraded CareDx from a hold rating to a buy rating in a research note on Friday, May 10th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and an average price target of $16.50.

View Our Latest Stock Analysis on CareDx

CareDx Trading Up 0.8 %

NASDAQ:CDNA opened at $15.63 on Friday. The stock has a 50 day moving average of $10.20 and a 200-day moving average of $9.99. The firm has a market capitalization of $814.01 million, a PE ratio of -4.57 and a beta of 1.51. CareDx has a 52 week low of $4.80 and a 52 week high of $16.15.

CareDx (NASDAQ:CDNAGet Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($2.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($1.97). CareDx had a negative return on equity of 55.08% and a negative net margin of 66.59%. The firm had revenue of $65.57 million during the quarter, compared to analyst estimates of $63.66 million. During the same period last year, the business earned ($0.34) EPS. The firm’s revenue was down 20.4% on a year-over-year basis. As a group, analysts predict that CareDx will post -1.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Citigroup Inc. raised its stake in CareDx by 7.1% during the 3rd quarter. Citigroup Inc. now owns 132,560 shares of the company’s stock valued at $928,000 after purchasing an additional 8,768 shares during the last quarter. Los Angeles Capital Management LLC raised its position in shares of CareDx by 138.9% during the fourth quarter. Los Angeles Capital Management LLC now owns 237,115 shares of the company’s stock valued at $2,845,000 after buying an additional 137,842 shares during the last quarter. ARK Investment Management LLC lifted its stake in shares of CareDx by 7.7% in the fourth quarter. ARK Investment Management LLC now owns 7,194,722 shares of the company’s stock valued at $86,337,000 after buying an additional 515,399 shares during the period. First Eagle Investment Management LLC grew its position in CareDx by 38.7% during the third quarter. First Eagle Investment Management LLC now owns 1,005,189 shares of the company’s stock worth $7,036,000 after buying an additional 280,345 shares in the last quarter. Finally, Swiss National Bank raised its holdings in CareDx by 2.3% in the 3rd quarter. Swiss National Bank now owns 118,200 shares of the company’s stock valued at $827,000 after acquiring an additional 2,700 shares in the last quarter.

CareDx Company Profile

(Get Free Report)

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.

Featured Articles

Analyst Recommendations for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.